Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

Clinical trial NCT05321212 · COMPLETED

Trial details

NCT number: NCT05321212
Sponsor: University Hospital, Brest
Status: COMPLETED
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung Immunotherapy

Start date: 2019-01-02
Primary completion: 2019-01-02
Enrollment: 108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.